Development of the Dy-166/Ho-166 in-vivo generator for radionuclide radiotherapy (original) (raw)

1993

Abstract

The in-vivo generator concept in radiotherapy implies internal deposition of a parent nuclide of intermediate half life and energy that decays in-vivo to a short-lived daughter which emits high-energy betas, thus increasing both half life and beta energy of the radiotherapeutic. The authors have extended this concept to injection of low radiation-dosage Dy-166 radiopharmaceuticals which generate significant activities of high-dose Ho-166 daughter product after only 1 day, thus sparing non-target tissues during localization. Produced by efficient double neutron capture on Dy-164, 81.6-hour Dy-166 can be conveniently and efficiently separated from 26.8-hour Ho-166 daughter by extraction column chromatography using chlorofluorohydrocarbon polymer support material and Di(2-ethylhexyl)-phosphoric acid as extractant. High purity Dy-166 can be obtained in about one hour and in a small volume in this manner.

Alan Ketring hasn't uploaded this paper.

Let Alan know you want this paper to be uploaded.

Ask for this paper to be uploaded.